Regeneron announced additional investments to its Limerick, Ireland biologics production facility.
Regeneron Pharmaceuticals is investing an additional $350 million in its Limerick Industrial Operations and Product Supply (IOPS) bioprocessing campus and will add another 200 jobs, bringing the total expected job creation in the Limerick, Ireland area to 500 jobs and total investment to $650 million by the end of 2017, the company announced on Oct. 19, 2015.
The US-based company acquired the former Dell Computer facility in Limerick and achieved planning approval in April 2014 for its first IOPS site outside of the United States. When the investment was initially announced in December 2013, a $300-million investment with 300 jobs was planned for delivery by the end of 2016. With this expansion of scope, the Limerick IOPS campus will house the largest-scale bulk biologics production facility in Ireland.
Regeneron's 400,000-ft2 biologics production facility in Limerick is now operational, with the first production line on track to enter validation before year-end 2015. Regeneron has worked closely with the Department of Jobs and IDA Ireland on the development of its operations in Ireland. In addition to the IOPS operations in Limerick, Regeneron also has a growing multi-functional team in Dublin supporting its business in Europe. Regeneron's total headcount in Ireland is expected to approach 550 by the end of 2017.
Source: Regeneron
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.